Prasetiyo P, Wahjoepramono E
J Clin Med. 2024; 13(15).
PMID: 39124599
PMC: 11313419.
DOI: 10.3390/jcm13154332.
Li G, Xu X, Cui J, Zhang F, Wang S
Exp Ther Med. 2023; 26(3):452.
PMID: 37614429
PMC: 10443066.
DOI: 10.3892/etm.2023.12151.
Wang Z, Li Z, Han C, Cheng Y, Wang K
In Vitro Cell Dev Biol Anim. 2022; 58(9):771-779.
PMID: 36203070
DOI: 10.1007/s11626-022-00722-6.
Meng X, Tian H, Guo W, Wang Z
Transl Neurosci. 2021; 12(1):456-468.
PMID: 34868669
PMC: 8605768.
DOI: 10.1515/tnsci-2020-0181.
Marconi G, Gallorini M, Carradori S, Guglielmi P, Cataldi A, Zara S
Molecules. 2019; 24(10).
PMID: 31130597
PMC: 6572653.
DOI: 10.3390/molecules24102005.
Sulforaphane from Cruciferous Vegetables: Recent Advances to Improve Glioblastoma Treatment.
Sita G, Hrelia P, Graziosi A, Morroni F
Nutrients. 2018; 10(11).
PMID: 30441761
PMC: 6267435.
DOI: 10.3390/nu10111755.
Overexpression of PLOD3 promotes tumor progression and poor prognosis in gliomas.
Tsai C, Huang L, Tsai W, Huang S, Lee J, Hueng D
Oncotarget. 2018; 9(21):15705-15720.
PMID: 29644003
PMC: 5884658.
DOI: 10.18632/oncotarget.24594.
circ-SHKBP1 Regulates the Angiogenesis of U87 Glioma-Exposed Endothelial Cells through miR-544a/FOXP1 and miR-379/FOXP2 Pathways.
He Q, Zhao L, Liu Y, Liu X, Zheng J, Yu H
Mol Ther Nucleic Acids. 2018; 10:331-348.
PMID: 29499945
PMC: 5862134.
DOI: 10.1016/j.omtn.2017.12.014.
NOS Expression and NO Function in Glioma and Implications for Patient Therapies.
Tran A, Boyd N, Walker K, Hjelmeland A
Antioxid Redox Signal. 2016; 26(17):986-999.
PMID: 27411305
PMC: 5467121.
DOI: 10.1089/ars.2016.6820.
Vascular Targeted Radioimmunotherapy for the Treatment of Glioblastoma.
Behling K, Maguire W, Lopez Puebla J, Sprinkle S, Ruggiero A, ODonoghue J
J Nucl Med. 2016; 57(10):1576-1582.
PMID: 27127217
PMC: 5050148.
DOI: 10.2967/jnumed.115.171371.
siRNA targeting YAP gene inhibits gastric carcinoma growth and tumor metastasis in SCID mice.
Zhou Z, Zhu J, Gao C, Li L, Zhou C, Wang H
Oncol Lett. 2016; 11(4):2806-2814.
PMID: 27073556
PMC: 4812121.
DOI: 10.3892/ol.2016.4319.
Does chronic hypertension prevent cancer progression?.
Mogi M, Horiuchi M
Hypertens Res. 2015; 38(11):711-2.
PMID: 26202180
DOI: 10.1038/hr.2015.87.
Single agent efficacy of the VEGFR kinase inhibitor axitinib in preclinical models of glioblastoma.
Lu L, Saha D, Martuza R, Rabkin S, Wakimoto H
J Neurooncol. 2014; 121(1):91-100.
PMID: 25213669
PMC: 4751887.
DOI: 10.1007/s11060-014-1612-1.
Direct effect of bevacizumab on glioblastoma cell lines in vitro.
Simon T, Coquerel B, Petit A, Kassim Y, Demange E, Le Cerf D
Neuromolecular Med. 2014; 16(4):752-71.
PMID: 25113866
DOI: 10.1007/s12017-014-8324-8.
Safety of bevacizumab in patients with malignant gliomas: a systematic review.
Simonetti G, Trevisan E, Silvani A, Gaviani P, Botturi A, Lamperti E
Neurol Sci. 2013; 35(1):83-9.
PMID: 24281944
DOI: 10.1007/s10072-013-1583-6.
Anti-cancer Therapies in High Grade Gliomas.
Tanase C, Enciu A, Mihai S, Neagu A, Calenic B, Cruceru M
Curr Proteomics. 2013; 10(3):246-260.
PMID: 24228024
PMC: 3821381.
DOI: 10.2174/1570164611310030007.
Pharmacokinetic assessment of efflux transport in sunitinib distribution to the brain.
Oberoi R, Mittapalli R, Elmquist W
J Pharmacol Exp Ther. 2013; 347(3):755-64.
PMID: 24113148
PMC: 3836310.
DOI: 10.1124/jpet.113.208959.
Updates in the management of high-grade glioma.
Bradley D, Rees J
J Neurol. 2013; 261(4):651-4.
PMID: 23857040
DOI: 10.1007/s00415-013-7032-x.
A multi-parametric imaging investigation of the response of C6 glioma xenografts to MLN0518 (tandutinib) treatment.
Boult J, Terkelsen J, Walker-Samuel S, Bradley D, Robinson S
PLoS One. 2013; 8(4):e63024.
PMID: 23638177
PMC: 3637165.
DOI: 10.1371/journal.pone.0063024.
Bevacizumab in high-grade gliomas: a review of its uses, toxicity assessment, and future treatment challenges.
Rahmathulla G, Hovey E, Hashemi-Sadraei N, Ahluwalia M
Onco Targets Ther. 2013; 6:371-89.
PMID: 23620671
PMC: 3633547.
DOI: 10.2147/OTT.S38628.